What Does a Residual Cancer Diagnosis Mean?

A residual cancer diagnosis means that cancer cells remain in the body after treatment, whether that treatment was surgery, chemotherapy, radiation, or some combination. The cells left behind can range from a visible mass a surgeon could see with the naked eye down to a scattering of tumor cells so sparse they are only detectable through molecular testing. The term covers a wide spectrum, and the implications for your health depend heavily on how much residual disease is present, where it is, and how it responds to further treatment.

Residual Disease After Surgery

One of the most straightforward forms of residual cancer is what surgeons call a positive surgical margin. When a tumor is removed, a pathologist examines the edges of the excised tissue under a microscope. If cancer cells extend to the cut edge, the assumption is that some tumor was left behind. A large database study of the ten most common solid cancers classified positive margins as microscopic residual tumor, macroscopic residual tumor (visible to the eye), or residual tumor not otherwise specified, and found hundreds of thousands of cases across those categories.

¹

A positive margin does not automatically mean the cancer will come back. Sometimes the body’s immune system clears stray cells, or subsequent treatments like radiation mop up what surgery missed. But positive margins do raise the risk of local recurrence, and your surgical team will typically discuss whether re-excision or additional therapy is warranted.

What Minimal Residual Disease Means

The term you will hear most often in modern oncology is minimal residual disease, or MRD. This refers to cancer cells that persist after treatment but at levels too low to detect through standard imaging or physical exams. MRD was first defined in blood cancers like leukemia and myeloma, where doctors could look for abnormal cells in bone marrow samples. It has since expanded to solid tumors, where fragments of tumor DNA circulating in the bloodstream serve as a proxy for hidden disease.

MRD is not a death sentence. In some patients, tiny amounts of residual disease remain dormant for years and never progress. In others, those cells eventually proliferate and cause a relapse. The critical distinction is whether the residual cells are stable or growing, and modern testing is increasingly able to tell the difference.

How Residual Cancer Is Detected

The tools used to find residual disease depend on the type of cancer and where you are in your treatment journey. They fall into a few broad categories.

Blood-Based Tests

Liquid biopsies look for traces of cancer in a simple blood draw. The most common target is circulating tumor DNA, or ctDNA, which are small fragments of DNA shed by tumor cells into the bloodstream. These tests can also pick up circulating tumor cells and tumor-specific microRNA.² ctDNA testing is increasingly used to identify actionable mutations for personalized therapy, detect MRD after treatment, and predict responses to immunotherapy.³ A growing body of evidence shows that detecting ctDNA after treatment for solid tumors predicts relapse.⁴

In blood cancers, the techniques are more established. Flow cytometry can spot one abnormal leukemia cell among 100,000 normal cells. Next-generation sequencing pushes that sensitivity even further, detecting one malignant cell in a million.⁵ Both methods have strengths. When compared head to head in acute myeloid leukemia, flow cytometry showed strong agreement with sequencing-based methods, though sequencing tends to catch more cases at the lowest disease levels.⁶

Imaging

PET scans, which measure how actively cells consume sugar, are particularly useful for distinguishing living tumor from scar tissue. After treatment for lung cancer, PET detected all cases of persistent or recurrent disease in one study, while standard CT was inconclusive in roughly a quarter of those same cases. PET achieved 100% sensitivity and 92% specificity for residual or recurrent non-small cell lung cancer, compared with 71% sensitivity for CT.⁷ In lymphoma, the advantage is similarly pronounced: CT alone has poor ability to tell whether a remaining mass is active cancer or just harmless scar, while PET can often make that distinction.⁸ PET’s ability to differentiate viable tumor from necrotic or fibrotic tissue is what makes it especially valuable in the post-treatment setting.⁹

Why the Amount Matters

Not all residual disease carries the same weight. In breast cancer, researchers developed a scoring system called the residual cancer burden, or RCB, to quantify how much disease remains after chemotherapy given before surgery. The system assigns scores from RCB-0 (no residual cancer, a complete pathologic response) through RCB-III (extensive residual disease). Patients with minimal residual disease, scored as RCB-I, had outcomes statistically indistinguishable from those with a complete response.¹⁰ Patients scored at RCB-III, by contrast, faced poor outcomes regardless of their hormone receptor status or other treatments.¹⁰

A larger pooled analysis of over 5,000 breast cancer patients confirmed that RCB score predicted long-term survival across all breast cancer subtypes. Each one-unit increase in the score was associated with meaningfully worse event-free survival, and this relationship held even after adjusting for age, tumor grade, and other baseline factors.¹¹

In blood cancers, the pattern is equally clear. A meta-analysis of multiple myeloma studies found that patients who achieved MRD negativity had a median progression-free survival of 54 months compared with 26 months for those who remained MRD-positive. Overall survival was 98 months versus 82 months.¹² In acute myeloid leukemia, the gap is even starker. A systematic review estimated five-year overall survival at roughly 68% for MRD-negative patients versus 34% for those still MRD-positive.¹³ In one specific AML study, patients who still had detectable mutant transcripts in their blood after treatment had an 82% relapse rate over three years, compared with 30% for those whose transcripts had cleared.¹⁴

How Residual Cells Survive Treatment

It is reasonable to wonder how cancer cells manage to survive chemotherapy or targeted therapy at all. The answer involves a biological trick called cellular dormancy. Residual tumor cells that endure treatment often enter a sleep-like state, pausing their growth cycle. In mouse models of breast cancer, researchers showed that residual cells surviving targeted therapy existed in this dormant state at both the primary tumor site and distant locations. These cells retained the ability to wake up and begin dividing again after extended quiet periods, eventually giving rise to recurrent tumors.¹⁵

Dormant cancer cells also deploy specific survival strategies. They shift their metabolism away from the pathways that chemotherapy drugs target, favor energy recycling through autophagy, and activate stress-response programs that protect them from drug damage.¹⁶ On a genetic level, treatment can actively reshape the surviving cancer population. Single-cell sequencing of myeloma patients found distinct evolutionary trajectories after therapy: in some patients, a resistant subclone was selected by the treatment and expanded, while in others, the surviving cells stabilized without obvious expansion.¹⁷

The immune system also plays a role. Residual cancer exists in a dynamic balance between tumor-cell survival and immune pressure. An active immune response can keep residual cells in check, killing some and releasing their DNA into the bloodstream in the process. A steadily rising ctDNA signal, on the other hand, more strongly suggests that residual disease is expanding beyond what the immune system can control.¹⁸

Early Warning of Relapse

One of the most promising applications of MRD testing is its ability to detect relapse months before it would show up on a scan or cause symptoms. In breast cancer, personalized ctDNA tracking detected metastatic relapse with a median lead time of about nine months before clinical detection, and in some patients, the warning came up to two years early.¹⁹ A separate study reported a similar median lead time of about eight months.²⁰ A systematic review and meta-analysis across broader breast cancer populations estimated a mean lead time of nearly 11 months from ctDNA detection to overt recurrence.²¹

That window of lead time matters because it creates an opportunity to intervene while the disease burden is still very low, although clinical trials are still working out exactly how best to use that information.

How MRD Results Change Treatment

MRD testing is beginning to reshape treatment decisions in two directions: intensifying therapy for patients who remain MRD-positive and, perhaps more importantly, de-escalating therapy for patients who test negative.

In multiple myeloma, the MASTER trial used MRD status to decide when patients could stop treatment entirely. Patients who achieved deep MRD negativity after intensive therapy stopped treatment and entered surveillance, while those who did not achieve that depth continued on maintenance therapy.²² Another trial assigned MRD-positive patients to more intensive consolidation, using their residual disease status to guide whether a second transplant or additional drug cycles were warranted.²³

The MRD2STOP study took this further, exploring whether myeloma patients who achieved very deep MRD negativity could safely discontinue maintenance therapy altogether. The results showed low rates of disease resurgence, particularly among patients who had cleared disease to extremely deep levels.²⁴ Emerging evidence from prospective studies suggests that maintenance may be safely discontinued in patients with sustained multimodal MRD negativity.²⁵

In colorectal cancer, MRD-negative status has been studied as a way to spare elderly patients from the harsher combination chemotherapy regimens. One analysis found that a simpler, single-drug regimen provided comparable disease-free survival to a more toxic combination in older patients who were MRD-negative, with a better safety profile.²⁶ A budget impact analysis estimated that incorporating ctDNA testing into colon cancer management could reduce costs by roughly 21% for commercial payers, largely by sparing MRD-negative patients from unnecessary adjuvant chemotherapy.²⁷

When the Tests Get It Wrong

No test is perfect, and MRD testing has its own pitfalls. False positives can occur, particularly with ctDNA assays. One known source of confusion is clonal hematopoiesis, a common age-related phenomenon in which blood stem cells accumulate mutations that mimic cancer-associated changes. Overlapping methylation patterns from non-cancer conditions can also produce misleading results, though improvements in databases and bioinformatics filtering are bringing false-positive rates down.²⁸

False negatives are also possible. A blood test can only detect what is being shed into the bloodstream, and some tumors shed very little DNA. The clinical utility of commercial ctDNA assays for detecting MRD in solid tumors after curative-intent treatment is still considered limited compared to their more established role in advanced disease settings.²⁹ A negative result is reassuring, but it does not guarantee that zero cancer cells remain. The ctDNA signal reflects both the number of viable cells and how quickly they are turning over, so a small, dormant tumor might not generate enough circulating DNA to cross the detection threshold.¹⁸

MRD as a Regulatory Endpoint

A significant shift happened in 2024 when the FDA’s Oncologic Drugs Advisory Committee unanimously voted to support MRD-negative complete response as an early endpoint for accelerated drug approval in multiple myeloma.³⁰ This is a practical big deal. Traditionally, new cancer drugs had to prove they improved progression-free survival or overall survival, endpoints that can take years to measure in a slow-moving disease like myeloma. If MRD negativity is accepted as a surrogate, trials can be smaller and faster, potentially getting effective drugs to patients sooner.

In acute myeloid leukemia, MRD is moving in the same direction, though formal regulatory acceptance as a primary trial endpoint has not yet been granted. Researchers have established the association between MRD negativity and longer survival,³¹ and validation studies are underway to support regulatory use as a co-primary endpoint, following the path myeloma has already taken.³²

The Emotional Side of Residual Cancer

Learning that cancer remains in your body, even at microscopic levels, carries real psychological weight. The anxiety surrounding follow-up scans and tests, often called scanxiety, is well documented. Among cancer patients studied for this phenomenon, common symptoms included trouble sleeping, feelings of dread, poor concentration, irritability, and restlessness, with roughly a quarter to a third of patients reporting each of these.³³ Patients with higher scanxiety consistently reported poorer quality of life, driven primarily by its impact on emotional well-being.

Fear of recurrence is closely tied to the MRD concept. In a study of young adult female breast and gynecological cancer survivors, 84% reported clinically meaningful fear of cancer recurrence, with 38% experiencing it at severe levels. Both fear of recurrence and scanxiety were associated with lower quality of life.³⁴ As MRD testing becomes more widespread, the number of patients living in this ambiguous space between “cancer-free” and “definitely relapsing” is growing. Clinicians are still figuring out the best way to communicate MRD results and manage the psychological burden that comes with knowing tiny amounts of disease may linger.

Who Gets Access to MRD Testing

Advanced genomic tools like next-generation sequencing and ctDNA assays remain expensive, and insurance coverage is uneven. Disparities in access to genomic testing have already been documented, with patients from racial and ethnic minority groups less likely to receive genotype-matched therapies than white patients even when their mutation profiles are similar.³⁵ If ctDNA-based MRD testing becomes standard for guiding treatment decisions, these existing inequities could widen. A patient whose insurer does not cover the test may end up receiving unnecessary chemotherapy (because no test proved they could safely skip it) or missing an early relapse signal. The economic analyses showing overall cost savings from MRD-guided treatment in colon cancer suggest that broader coverage could actually reduce total spending,²⁷ but the upfront per-test cost remains a barrier for individual patients and health systems that have not yet adopted it.